ALKEM LABORATORIES | GSK PHARMA | ALKEM LABORATORIES/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 24.6 | -81.9 | - | View Chart |
P/BV | x | 5.9 | 12.2 | 48.6% | View Chart |
Dividend Yield | % | 0.8 | 1.3 | 63.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALKEM LABORATORIES Mar-20 |
GSK PHARMA Mar-19 |
ALKEM LABORATORIES/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 2,720 | 3,595 | 75.7% | |
Low | Rs | 1,660 | 1,253 | 132.5% | |
Sales per share (Unadj.) | Rs | 697.9 | 184.7 | 377.9% | |
Earnings per share (Unadj.) | Rs | 96.1 | 26.3 | 365.6% | |
Cash flow per share (Unadj.) | Rs | 117.3 | 29.2 | 402.1% | |
Dividends per share (Unadj.) | Rs | 25.00 | 20.00 | 125.0% | |
Dividend yield (eoy) | % | 1.1 | 0.8 | 138.3% | |
Book value per share (Unadj.) | Rs | 515.2 | 126.3 | 407.9% | |
Shares outstanding (eoy) | m | 119.57 | 169.40 | 70.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 3.1 | 13.1 | 23.9% | |
Avg P/E ratio | x | 22.8 | 92.2 | 24.7% | |
P/CF ratio (eoy) | x | 18.7 | 83.1 | 22.5% | |
Price / Book Value ratio | x | 4.3 | 19.2 | 22.2% | |
Dividend payout | % | 26.0 | 76.1 | 34.2% | |
Avg Mkt Cap | Rs m | 261,879 | 410,626 | 63.8% | |
No. of employees | `000 | 14.3 | 5.0 | 288.9% | |
Total wages/salary | Rs m | 15,055 | 5,372 | 280.2% | |
Avg. sales/employee | Rs Th | 5,822.6 | 6,306.7 | 92.3% | |
Avg. wages/employee | Rs Th | 1,050.5 | 1,083.1 | 97.0% | |
Avg. net profit/employee | Rs Th | 802.0 | 898.0 | 89.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 83,444 | 31,281 | 266.8% | |
Other income | Rs m | 1,042 | 1,023 | 101.9% | |
Total revenues | Rs m | 84,486 | 32,304 | 261.5% | |
Gross profit | Rs m | 14,734 | 6,009 | 245.2% | |
Depreciation | Rs m | 2,528 | 486 | 520.1% | |
Interest | Rs m | 651 | 6 | 10,843.3% | |
Profit before tax | Rs m | 12,598 | 6,540 | 192.6% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 287 | 0.0% | |
Tax | Rs m | 1,105 | 2,373 | 46.6% | |
Profit after tax | Rs m | 11,493 | 4,454 | 258.0% | |
Gross profit margin | % | 17.7 | 19.2 | 91.9% | |
Effective tax rate | % | 8.8 | 36.3 | 24.2% | |
Net profit margin | % | 13.8 | 14.2 | 96.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 54,960 | 20,061 | 274.0% | |
Current liabilities | Rs m | 32,433 | 14,543 | 223.0% | |
Net working cap to sales | % | 27.0 | 17.6 | 153.0% | |
Current ratio | x | 1.7 | 1.4 | 122.8% | |
Inventory Days | Days | 80 | 57 | 140.2% | |
Debtors Days | Days | 72 | 14 | 513.1% | |
Net fixed assets | Rs m | 32,710 | 14,343 | 228.1% | |
Share capital | Rs m | 239 | 1,694 | 14.1% | |
"Free" reserves | Rs m | 61,368 | 19,704 | 311.4% | |
Net worth | Rs m | 61,607 | 21,398 | 287.9% | |
Long term debt | Rs m | 1,592 | 2 | 79,620.0% | |
Total assets | Rs m | 99,433 | 39,113 | 254.2% | |
Interest coverage | x | 20.4 | 1,091.0 | 1.9% | |
Debt to equity ratio | x | 0 | 0 | 27,655.0% | |
Sales to assets ratio | x | 0.8 | 0.8 | 104.9% | |
Return on assets | % | 12.2 | 11.4 | 107.1% | |
Return on equity | % | 18.7 | 20.8 | 89.6% | |
Return on capital | % | 21.0 | 31.9 | 65.7% | |
Exports to sales | % | 19.1 | 0 | - | |
Imports to sales | % | 3.0 | 0 | - | |
Exports (fob) | Rs m | 15,917 | NA | - | |
Imports (cif) | Rs m | 2,483 | NA | - | |
Fx inflow | Rs m | 16,061 | 534 | 3,007.7% | |
Fx outflow | Rs m | 2,483 | 7,091 | 35.0% | |
Net fx | Rs m | 13,578 | -6,557 | -207.1% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 5,851 | 3,994 | 146.5% | |
From Investments | Rs m | -7,414 | -1,433 | 517.2% | |
From Financial Activity | Rs m | 792 | -3,584 | -22.1% | |
Net Cashflow | Rs m | -731 | -1,023 | 71.5% |
Indian Promoters | % | 66.9 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 50.7 | - | |
Indian inst/Mut Fund | % | 33.1 | 10.2 | 324.5% | |
FIIs | % | 0.0 | 23.8 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 0.0 | 15.4 | - | |
Shareholders | 68,381 | 102,036 | 67.0% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALKEM LABORATORIES With: NEULAND LABS DR. REDDYS LAB ABBOTT INDIA ALEMBIC PROCTER & GAMBLE HEALTH
Compare ALKEM LABORATORIES With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
After staging a gap-up opening, Indian share markets extended gains as the session progressed and rallied nearly 2%, boosted by realty and finance stocks.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.
More Views on NewsThe smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
Our ace stock picker is ready to capitalise on a big growth opportunity.
More